Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Average: 2009-2025

Historic Equity Average for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $7.4 million.

  • China Pharma Holdings' Equity Average rose 6.02% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 6.02%. This contributed to the annual value of $7.6 million for FY2024, which is 29.44% up from last year.
  • China Pharma Holdings' Equity Average amounted to $7.4 million in Q3 2025, which was up 10.01% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Equity Average registered a high of $7.9 million during Q1 2024, and its lowest value of $3.4 million during Q3 2022.
  • In the last 3 years, China Pharma Holdings' Equity Average had a median value of $7.0 million in 2024 and averaged $6.6 million.
  • Its Equity Average has fluctuated over the past 5 years, first crashed by 48.73% in 2022, then spiked by 90.39% in 2023.
  • Over the past 5 years, China Pharma Holdings' Equity Average (Quarterly) stood at $6.4 million in 2021, then crashed by 44.65% to $3.6 million in 2022, then soared by 90.39% to $6.8 million in 2023, then climbed by 5.24% to $7.1 million in 2024, then increased by 6.02% to $7.4 million in 2025.
  • Its Equity Average stands at $7.4 million for Q3 2025, versus $6.7 million for Q2 2025 and $7.4 million for Q1 2025.